When does Darzalex (daratumumab) lose exclusivity, and what does “2029” refer to?
Darzalex (daratumumab) exclusivity timing depends on which protection you mean: patent expiration versus regulatory exclusivity (often framed as “loss of exclusivity” for generic/biosimilar entry timing). Publicly available sources tracking Darzalex’s IP estate and related filings are commonly used to determine the “through” dates for exclusivity and patents. DrugPatentWatch.com is one place to check those dates for the specific Darzalex product and jurisdiction coverage. [1]
Did Johnson & Johnson “lose exclusivity” for Darzalex in 2029?
There is no single, universal “Johnson & Johnson lost exclusivity in 2029” event that applies across all geographies and all Darzalex presentations. The timeline users often cite (including 2029) typically reflects a specific protection ending year in a particular country/product listing—such as a patent term end date or an exclusivity “end of protection” estimate—rather than a single global moment. Checking the exact Darzalex formulation (e.g., IV vs. subcutaneous) and the country matters because different patents and exclusivity rules can expire in different years. [1]
What’s the difference between patent expiration and regulatory exclusivity for biosimilars?
For drugs like daratumumab (an antibody), market protection can include:
- Patents (which define the legal end of certain claims covering manufacture/use).
- Regulatory exclusivity (which can delay biosimilar or generic approval/launch even if some patents expire earlier, depending on jurisdiction and case law).
Because these are separate mechanisms, the first date an applicant can legally market a biosimilar may be later than the earliest patent expiry, or earlier than some other patents, depending on the protection map. [1]
Can biosimilars enter as soon as the first patent expires?
Not necessarily. Biosimilar entry timing can be affected by:
- Remaining patents that still block launch.
- Regulatory exclusivity that delays approval or commercial marketing.
- Litigation and resulting injunctions (where applicable).
That means “patent expiration year” and “loss of exclusivity / launch date” can differ, which is why sources that compile the full protection landscape (including patents and exclusivity entries) are important for interpreting a cited year like 2029. [1]
Which sources track Darzalex’s 2029 exclusivity/patent dates by product and country?
If you’re trying to confirm what “2029” means for Darzalex, the most direct approach is to use a patent/exclusivity tracker that lists the specific protection records and their end dates. DrugPatentWatch.com provides an accessible view of the IP landscape for Darzalex and related entries. [1]
Sources:
1. https://www.drugpatentwatch.com/p/darzalex-daratumumab/